Hexanol

DGAP-News: AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE(R)AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Retrieved on: 
Wednesday, December 22, 2021
Lynx, Drug development, Epitope, Conditional sentence, Technology, Hexanol, Doctor of Philosophy, Risk, Patient, Cardiovascular disease, European Journal, PCSK9, CEO, Huntington's disease, European Journal of Clinical Pharmacology, Frontier, Peter Zeitlinger, Protein, Hypercholesterolemia, Immune system, AG, Trial of the century, Company, Antibody, SAIT, Immunization, Death, Immunotherapy, Pharmaceutical industry, Vaccine, Greater, AFFITOPE(R) AT04, AFFiRiS AG:, Frontier Biotechnologies Inc.:, AFFITOPE(R) AT04, AFFIRIS AG:, FRONTIER BIOTECHNOLOGIES INC.:

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE(R)AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Key Points: 
  • AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE(R)AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
    The issuer is solely responsible for the content of this announcement.
  • AFFITOPE(R) AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published.
  • Frontier Biotechnologies will be responsible for all development costs for AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.
  • In addition to its active immunotherapy AT04, AFFiRiS' pipeline also includes the monoclonal antibody mAB C6-17 targeting mutated huntingtin (mtHTT) protein, which causes Huntington's disease.

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Retrieved on: 
Wednesday, December 22, 2021
Lynx, Drug development, Epitope, Conditional sentence, Technology, Hexanol, Doctor of Philosophy, Risk, Patient, Cardiovascular disease, European Journal, PCSK9, CEO, European Journal of Clinical Pharmacology, Frontier, Peter Zeitlinger, Protein, Hypercholesterolemia, Greater, Immune system, AG, Trial of the century, Antibody, SAIT, GLOBE, Immunization, Death, Immunotherapy, Partnership, Pharmaceutical industry, Fine chemical, Vaccine

AFFITOPE AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published.

Key Points: 
  • AFFITOPE AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published.
  • Frontier Biotechnologies will beresponsible for all development costs for AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.
  • Noel Barrett, PhD, CEO of AFFiRiS AG commented: This collaboration further validates our AFFITOME technology platform.
  • In addition to its active immunotherapy AT04, AFFiRiS pipeline also includes the monoclonal antibody mAB C6-17 targeting mutated huntingtin (mtHTT) protein, which causes Huntingtons disease.

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021

Retrieved on: 
Friday, November 12, 2021
MAST, Clinical trial, MRE, Metabolic syndrome, Non-alcoholic fatty liver disease, Doctor's visit, Principal, Pain, ELF, Disclosure, Therapy, Accelerated approval (FDA), Webcast, Communication, University of Oxford, Safety, Biomarker, Blood pressure, NAFLD, Research, Forward-looking statement, Hexanol, Liver, Liver disease, GLOBE, Cirrhosis, CAP, Time, Patient, FDA, Achievement, Private Securities Litigation Reform Act, Fatty liver disease, U.S. Securities and Exchange Commission, Hepatomegaly, NASDAQ, Knowledge, Inflammation, Risk, Non-cirrhotic portal fibrosis, AST, SEC, SGLT2, Elastography, Steatosis, Triglyceride, Annual report, PHASE 2, Judgement, Fibrosis, THR, Nasdaq, Pharmaceutical industry, Medical imaging

These new data from MAESTRO-NAFLD-1, our ongoing Phase 3 non-invasive study of resmetirom in patients with presumed NASH, reinforce and deepen our understanding of the therapeutic potential of resmetirom.

Key Points: 
  • These new data from MAESTRO-NAFLD-1, our ongoing Phase 3 non-invasive study of resmetirom in patients with presumed NASH, reinforce and deepen our understanding of the therapeutic potential of resmetirom.
  • Late-Breaking Poster Presentation (abstract #LP19): Friday, November 12th
    Biomarkers, imaging and safety in resmetirom 52-week non-cirrhotic NASH Phase 3 clinical trial, completed open-label arm of MAESTRO-NAFLD-1.
  • NASH cirrhotics with elevated baseline liver fat >=8% had 30% reduction in liver fat fraction and 18% reduction in liver volume.
  • Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made.

India 2-Ethyl Hexanol Comprehensive Techno-Commercial Market Study, 2013-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 31, 2019
Chemicals, Plastics, Manufacturing, Building materials, Organic compounds, Chemistry, Monomers, Cement, Concrete, Plasticizer, Hexanol, Phthalate, Methacrylate, Ethyl

The "India 2-Ethyl Hexanol Comprehensive Techno-Commercial Market Study, 2013-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India 2-Ethyl Hexanol Comprehensive Techno-Commercial Market Study, 2013-2030" report has been added to ResearchAndMarkets.com's offering.
  • The demand for 2-Ethyl Hexanol in India stood at more than 100 KTPA in 2018 and is projected to grow at a healthy growth rate during the forecast period.
  • 2-Ethyl Hexanol is majorly used to manufacture plasticizers, especially dioctyl phthalate (DOP) and 2-Ethyl Hexanol derivatives.
  • Moreover, increasing manufacturing of 2-Ethyl Hexanol derivatives, acrylate and methacrylate esters is further expected to fuel the demand for 2-Ethyl Hexanol during the forecast period.